Midas Database for Drug Pricing and Utilization, including Disease and Patient functionality

The Patented Medicine Prices Review Board (PMPRB) has awarded a sole-source contract to IQVIA SOLUTIONS CANADA INC. for the provision of the MIDAS database, a comprehensive pharmaceutical pricing and utilization system serving as a critical tool for monitoring drug prices and detecting potential patent abuse in Canada. The contract, effective from May 1, 2026, through March 31, 2029, with two optional one-year extensions, encompasses the supply of a fully operational, commercially available database containing detailed drug utilization and pricing data for both retail and hospital sectors across Canada and all 31 OECD member countries. Data must be collected objectively from hospitals, pharmacies, and wholesalers, and must include historical records spanning at least ten years, segmented by market type (patented, generic, off-patent), distribution level (ex-factory, wholesale, retail), therapeutic classification (ATC4), and currency (local and U.S. dollar). The database must support 24/7 online access via a business intelligence platform with export functionality to Excel, CSV, and PDF formats, alongside customizable reporting, automated updates, and annual training and analytical support totaling at least 15 hours per year. The supplier must have a proven track record of at least ten years in pharmaceutical data collection using methodologies aligned with the Agreement on Comparative Analyses of Pharmaceuticals (ACAN), and the system must provide minimum data elements including manufacturer identification, international nonproprietary names, anatomical therapeutic codes, pharmaceutical form, strength, packaging size, and pricing metrics such as median, minimum, and maximum values at each level of the supply chain. The contract value is estimated at $1,827,550.32 USD, covering the base period and all optional extensions. Delivery and performance are centered in Ottawa, Canada, with data collection occurring globally, and acceptance occurs upon confirmation that all technical requirements—ranging from data completeness and segmentation to system accessibility and reporting capabilities—are fully met. Intellectual property rights for any enhancements or new data elements developed under the contract remain with IQVIA, and no security clearances, key personnel mandates, or organizational conflict of interest clauses are stipulated. The acquisition was conducted under Government Contracts Regulations subsection 6(d), recognizing IQVIA as the sole provider with the exclusive capability to deliver a database of this scope, depth, and objectivity, and the procurement follows an LPTA model with no formal scoring weights or trade-off analysis applied.